Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …

Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

RNA sequencing (RNAseq) can reveal gene fusions, splicing variants, mutations/indels in
addition to differential gene expression, thus providing a more complete genetic picture than …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

Abstract PD-1 blockade unleashes CD8 T cells, including those specific for mutation-
associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit …